Sonoma Pharmaceuticals (SNOA) Finished Goods (2012 - 2025)

Sonoma Pharmaceuticals' Finished Goods history runs 13 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• On a quarterly basis, Finished Goods fell 2.74% year-over-year to $2.0 million in Q4 2025; TTM through Dec 2025 was $2.0 million, a 2.74% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, up 49.88% from the prior year.
• Finished Goods declined to $2.0 million in Q4 2025 per SNOA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $2.4 million in Q2 2025 and bottomed at $773000.0 in Q3 2021.
• The 5-year median for Finished Goods is $1.2 million (2021), against an average of $1.4 million.
• Across the five-year window, Finished Goods sank 51.87% in 2021 and jumped 91.92% in 2025, its largest moves.
• Year by year, Finished Goods stood at $1.3 million in 2021, then fell by 1.12% to $1.2 million in 2022, then climbed by 16.96% to $1.4 million in 2023, then jumped by 38.54% to $2.0 million in 2024, then dropped by 2.74% to $2.0 million in 2025.
• Per Business Quant, the three latest SNOA Finished Goods figures stand at $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.4 million (Q2 2025).